Tenaya Therapeutics, Inc. SEC filings TNYA
Tenaya Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to May 7, 2021. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Agreement ended
|
Jul 2, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 29, 2026 | May 27, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2026 | Mar 11, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 5, 2026 | Mar 4, 2026 |
| 8-K |
Current report
Listing notice, Officer or director change
|
Jan 30, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 12, 2025 | Dec 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 11, 2025 | Dec 11, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Other events
|
Nov 7, 2025 | Nov 7, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 30, 2025 | May 28, 2025 |
| 8-K |
Current report
Results of operations
|
May 7, 2025 | May 7, 2025 |
| 8-K |
Current report
Listing notice
|
Apr 18, 2025 | Apr 15, 2025 |
| 8-K |
Current report
Exit or restructuring costs
|
Mar 28, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Mar 4, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 7, 2025 | Feb 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 28, 2025 | Jan 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 17, 2024 | Dec 17, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 17, 2024 | Dec 16, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2024 | Sep 12, 2024 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 25, 2024 | Jul 19, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 27, 2024 | Jun 25, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 31, 2024 | May 30, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
May 14, 2024 | May 13, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2024 | Mar 18, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Feb 8, 2024 | Feb 7, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2023 | Nov 8, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2023 | Aug 9, 2023 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 12, 2023 | Jun 8, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 21, 2023 | Mar 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 13, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 7, 2022 | Dec 5, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 17, 2022 | Nov 16, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Material agreement
|
Aug 10, 2022 | Aug 10, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2022 | Aug 10, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2022 | Jun 9, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2022 | Mar 23, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 22, 2021 | Dec 22, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 22, 2021 | Nov 17, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2021 | Sep 8, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 3, 2021 | Aug 3, 2021 |
Showing 54 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TNYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1858848
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.